

8 January 2026

Osteopore signs exclusive licensing agreement for innovative technology that accelerates bone and tissue regeneration

Highlights

- Osteopore signs exclusive licensing agreement with Accelerate Technologies Pte Ltd (Accelerate), A*STAR's technology transfer arm, for an innovative bioactive technology designed to accelerate bone and tissue regeneration. A*STAR is Singapore's lead public sector R&D agency.
- This technology puts Osteopore in the position to tap on new markets including the bone morphogenetic protein-2 (BMP-2) market. The Asia Pacific (APAC) BMP-2 market size was USD 670m in 2024, and will grow at a Compound Annual Growth Rate of 8.5% from 2024 to 2031¹.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the signing of an exclusive license with Accelerate for an innovative bioactive technology platform, Heparan Sulphate, designed to accelerate bone and tissue regeneration.

Osteopore has been working with the Institute of Molecular and Cell Biology (IMCB), A*STAR Research Entities, to incorporate various types of Heparan Sulphate with Osteopore's

¹ <https://www.cognitivemarketresearch.com/regional-analysis/asia-pacific-bone-morphogenetic-protein-bmp-2-market-report>



technology. This combination has the potential to provide unprecedented clinical outcomes by significantly improving the rate and quality of bone regeneration, leading to faster recovery times, reduced complications, and improved overall patient health.

In April 2024, Osteopore initiated a human clinical trial at the National University Hospital Singapore (NUHS), combining Heparan Sulphate 3 (HS3), a molecule targeting bone morphogenetic protein-2 (BMP-2), with Osteopore's regulatory-approved product for the treatment of medial wedge opening High Tibial Osteotomy (MWOHTO) in up to 12 patients - this clinical study is in progress.⁴

The exclusive license for the Heparan Sulphate technology covers two families of Heparan Sulphate (including HS3) for all life science and medical use, research and clinical use, including patents and knowhow. The countries covered by the exclusive license include the United States of America, the European Union, and China.

This exclusive license is for a 15-year period, and provides for an upfront payment, royalties linked to sales, and additional payments upon the achievement of market approval milestones. Whilst the specific financial terms are confidential, the Company advises that it does not anticipate the license arrangement to have an immediate or short-term material impact on its operating results.

Based on the latest industry report published in November 2025⁶, the Asia Pacific (APAC) BMP-2 market size was USD 670m in 2024 and will grow at a Compound Annual Growth Rate of

⁴ ASX Announcement, 23 April 2024.

⁶ <https://www.cognitivemarketresearch.com/regional-analysis/asia-pacific-bone-morphogenetic-protein-bmp-2-market-report>



8.5% from 2024 to 2031. China, Japan and South Korea represent the three largest market opportunities in APAC.

Commenting on the exclusive licensing agreement, CEO Dr Yujing Lim, said:

"We are delighted to onboard an important innovative platform technology that strengthens Osteopore's position in regenerative medicine.

"This new technology platform has the potential to challenge current treatment options due to its enhanced safety profile and stronger consistency of results.

"The territory covered by the patents and knowhow aligns with our expansion strategy, and is an exciting addition to our technology and future product portfolio.

"We are now entering the early stages of commercialising this technology, and will undertake the process in line with current regulatory requirements", said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim

Chief Executive Officer

Osteopore Limited

E: lim_yujing@osteopore.com

Mark Leong

Executive Chairman

Osteopore Limited

E: mark_leong@osteopore.com

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy



bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

